Tag: Phase II Trial
Study: Few People with Peanut Allergy Tolerate Peanut after Stopping OIT
Continuing with a modest dose confers more protection, NIH-funded study finds.
New Peanut Allergy Treatment Passes Phase 2 Trial, Shows Effectiveness and...
UNC School of Medicine researchers show that tiny under-the-tongue doses of peanut protein can offer safe and substantial protection against peanut allergy.
Aimmune Enrolls First Patient in Phase 2 Trial of AR201 for...
AR201 is the second development program that Aimmune is advancing to phase 2 using its Characterized Oral Desensitization ImmunoTherapy (CODIT™) platform.
Aimmune to Begin Phase 2 Trials of Egg Allergy OIT Candidate
AR201 for Egg Allergy Phase 2 Initiation Planned for 2019.
Aimmune Therapeutics Announces Initiation of Phase 2 Study of AR101 With...
Trial Will Build on the Positive, Pivotal Phase 3 PALISADE Trial of AR101.
Phase II Trials of AR101 with Dupilumab for Peanut Allergy to...
Study scheduled to commence next week.
Enrollment Complete for Phase 2b Probiotic Oral Immunotherapy Treatment Candidate
Study to provide evidence of longer lasting tolerance to peanut in a larger number of patients.
Milk and Peanut Clinical Trial Advances
Announcements regarding two food allergy therapies that are in or advancing toward clinical trials were made yesterday.
Study: Drug Increases Speed and Safety of OIT for Multiple Allergies
Combining omalizumab with OIT is safe and effective for treating multiple food allergies simultaneously.
Aimmune, Regeneron and Sanofi Collaborate on Combination Peanut Therapy
More exciting news as pharma companies work to extend the effectiveness of their therapies in combination.
